Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

Inclusion Criteria: * Diagnosed B cell malignancies including: B-cell Acute Lymphoblastic Leukemia (B-ALL) and B cell lymphomas (DLBCL、FL、MZL、LPL、HCL、CLL、BL、MCL) * Refractory/Relapsed B cell malignancies: * Age 6-80 years, male or female * Nidus could be evaluated: minimum diameter of single nidus ≥10mm, and/or tumor cells in bone marrow ≥ 5% * ECOG≤2 points * Function of main organs or tissues were functional: Liver - ALT/AST≤3 normal upper limit, Serum total bilirubin (TBIL) ≤2 normal upper limit; Kidney - glomerular filtration rate (GFR) \> 60 mL/min/1.73 m2 or serum creatinine in normal range; Lunge - carbon monoxide diffusion capacity (DLCO) or forced expiratory volume in 1s (FEV) \>45% estimate; Heart - left ventricular ejection fraction (LVEF) ≥50% * Expecting life span ≥3 months * No chemotherapy, radiation therapy or immunotherapy in 2 weeks before enrollment * Fertile females/males consented to use contraceptives during participation of the trial * Patient or his/her custodia could understand and is willing to sign the written consent Exclusion Criteria: * Pregnancy or lactation * Couldn't use contraceptives during participation of the trial * Couldn't collect enough monocyte * Active and/or severe infection * HIV infection, active Hepatitis B or Hepatitis C infection * Had active autoimmune disease * Had non-melanoma skin carcinoma (NMSC) or Carcinoma in situ (e.g. cervix, bladder, galactophore) * Obvious clinical encephalopathy or novel neuron function damage * Organ failure: Heart - upper than NYHA level III or had uncontrolled malignant arrhythmia; Liver - upper than level III of Wuhan conference classification; Kidney - kidney failure stage3 or worse * Using immunosuppressive drugs or adreno-cortical hormone (ACH) within two weeks of enrollment * Insufficient T cell number or T cell transfection rate * Needed urgent disease controlling due to tumor load * Patients had biological treatment, immunotherapy or radiation therapy within 6 weeks prior to enrollment or are currently under these treatment * Substance abuse or drug addiction * lack of compliance, communication deficit or other unaccommodated situations